About this trial
Social media use has been linked to negative mental health outcomes, including increased anxiety, depression, stress, poor sleep quality, and difficulties in emotion regulation. Digital detox interventions, which involve reducing or temporarily eliminating digital engagement, have emerged as a strategy to mitigate these effects. However, current evidence regarding their effectiveness is mixed and limited by short-term follow-ups and methodological variability. This study aims to examine the impact of a digital detox intervention on depression, anxiety, stress, sleep quality, and emotion regulation in young adults.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Owning a smartphone
Using social media for ≥ 8 hours per day
Not having a diagnosis related to anxiety, depression, stress, sleep, or emotional regulation
Living in an environment with internet access
Disqualifiers
Having a history of psychiatric diagnosis
Currently using psychiatric medication
Having received psychological counseling in the past 6 months
Having a diagnosis of sleep disorder
Trial design
Parallel
Treatments tested in this trial
digital detox
BehavioralThe digital detox intervention differs from other clinical interventions in several key aspects. Unlike pharmacological treatments or traditional psychotherapy, it focuses on behavioral modification by intentionally reducing or eliminating engagement with digital devices and social media for predetermined periods. The intervention emphasizes mindful technology use, limits screen time, and encourages offline activities to restore emotional balance and improve sleep quality. Additionally, it targets the cumulative effects of constant digital exposure, such as information overload, social comparison, and digital dependency, which are not typically addressed in standard mental health interventions. This unique focus on managing digital behavior positions digital detox as a complementary strategy for promoting psychological well-being in young adults.
Treatment groups
Trial outcomes
Primary outcomes
DASS 21
The DASS-21 was developed by Lovibond and Lovibond as a shortened version of the DASS-42. The psychometric properties of the Turkish version of the Depression Anxiety Stress-21 (DASS-21) scale in both clinical and non-clinical samples were examined by Sarıçam. In the non-clinical sample, the test-retest correlation coefficients were found to be r = 0.68 for the depression subscale, r = 0.66 for the anxiety subscale, and r = 0.61 for the stress subscale. This scale is a 4-point Likert-type instrument consisting of seven items for each of the three dimensions: depression, anxiety, and stress. A score of 5 or above on the depression subscale, 4 or above on the anxiety subscale, and 8 or above on the stress subscale indicates the presence of the respective problem
PUKİ
The Pittsburgh Sleep Quality Index (PSQI) was developed by Buysse et al. and its validity and reliability in Turkey were established by Ağargün et al. The scale assesses an individual's sleep quality over the past month and consists of 24 items. Nineteen of these are self-report questions, and 18 items are scored across seven components: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction. Each item is rated on a 0-3 scale, with total scores ranging from 0 to 21. Scores of 5 or below indicate "good sleep quality," while scores above 5 indicate "poor sleep quality." The scale demonstrates a high level of internal consistency with a Cronbach's alpha of 0.80, and its diagnostic sensitivity (89.6%) and specificity (86.5%) are also high.
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Ataturk University
Lead sponsor
Agri Ibrahim Cecen University
Sponsor institution
This trial is not recruiting at the moment. You can still explore other options: